30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Barry Quart

Track

Insider profile

Currently holds positions in Kiniksa Pharmaceuticals Ltd, Ardea Biosciences Inc and Heron Therapeutics Inc

Performance

Overall performance
2.5
Performance over holding periods
2.5
30 days 90 days 120 days
Average return 6% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
4 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Kiniksa Pharmaceuticals Ltd Oct. 1, 2015 -
President, Chief Executive Officer, Director Ardea Biosciences Inc June 20, 2012 -
President, Chief Executive Officer, Director Heron Therapeutics Inc Feb. 5, 2019 -
Chief Executive Officer, Director Heron Therapeutics Inc April 24, 2017 - Feb. 5, 2019
Chief Executive Officer, Interim Principal Financial Officer, Interim Principal Accounting Officer, Director Heron Therapeutics Inc April 1, 2017 - April 24, 2017
Chief Executive Officer, Director Heron Therapeutics Inc May 1, 2013 - April 1, 2017
Independent Director Heron Therapeutics Inc June 18, 2012 - May 1, 2013
President, Chief Executive Officer, Director Ardea Biosciences Inc Dec. 21, 2006 - June 19, 2012
Barry Quart's trades of Kiniksa Pharmaceuticals Ltd's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-29 2026-04-28
PlS Planned sale
16,793 +3.6%
44.95
US$4,592,563 		16,793 +3.6% 44.95 US$4,592,563
2026-04-08 2026-04-06
PlS Planned sale
258 +32.8%
109.68
US$3,291,981 		258 +32.8% 109.68 US$3,291,981
2026-04-06 2026-04-06
PrS Proposed sale
67,792
248.30
US$2,147,876 		67,792 248.30 US$2,147,876
2026-02-12 2026-02-12
PlS Planned sale
2,690 -17.7%
45.00
US$121,050 		2,690 -17.7% 45.00 US$121,050
2026-02-12 2026-02-10
PlS Planned sale
110 -0.9%
45.00
US$4,950 		110 -0.9% 45.00 US$4,950
2026-02-04 2026-02-04
PlS Planned sale
2,602 -17.2%
45.02
US$117,142 		2,602 -17.2% 45.02 US$117,142
2026-02-04 2026-02-04
PlS Planned sale
2,602 -17.2%
45.02
US$117,142 		2,602 -17.2% 45.02 US$117,142
2026-02-04 2026-02-03
PlS Planned sale
12,528 -50.0%
45.27
US$567,143 		12,528 -50.0% 45.27 US$567,143
2026-02-04 2026-02-03
PlS Planned sale
12,528 -50.0%
45.27
US$567,143 		12,528 -50.0% 45.27 US$567,143
2026-02-04 2026-02-02
PlS Planned sale
830 -6.2%
45.00
US$37,350 		830 -6.2% 45.00 US$37,350
2026-02-04 2026-02-02
PlS Planned sale
830 -6.2%
45.00
US$37,350 		830 -6.2% 45.00 US$37,350
2025-12-17 2025-12-15
PlS Planned sale
20,129 -61.6%
41.51
US$835,555 		20,129 -61.6% 41.51 US$835,555
2025-12-15 2025-12-15
PrS Proposed sale
58,889
41.51
US$2,444,530 		58,889 41.51 US$2,444,530
2025-06-11 2025-06-11
S Sale
12,336 -49.6%
30.39
US$374,891 		12,336 -49.6% 30.39 US$374,891
2025-06-11 2025-06-10
S Sale
8,212 -39.6%
30.36
US$249,316 		8,212 -39.6% 30.36 US$249,316
2025-06-11 2025-06-09
S Sale
6,900 -35.5%
30.26
US$208,794 		6,900 -35.5% 30.26 US$208,794
2025-06-09 2025-06-09
PrS Proposed sale
27,448
30.26
US$830,576 		27,448 30.26 US$830,576
2022-12-01 2022-11-29
S Sale
21,959 -100.0%
16.15
US$354,638 		21,959 -100.0% 16.15 US$354,638
2019-10-04 2019-10-03
B Purchase
4,571 +5.1%
17.50
US$79,992 		4,571 +5.1% 17.50 US$79,992